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The role of Endothelin-1 (ET-1) in the central nervous system is not fully understood yet although several studies strongly support its
neuromodulatory role. A high density of endothelin receptors is present in the dorsal vagal complex that is the major site for the regulation of the
digestive function. Therefore in the present study we sought to establish the role of ET-1 in the central regulation of bile secretion in the rat.
Intracerebroventricular ET-1 injection exhibited opposite behaviors on spontaneous bile secretion according to the dose administered. Lower doses
of ET-1 (1 fM) increased bile flow and bicarbonate excretion whereas higher doses (1 nM) decreased bile flow and bile acid output. Both the
choleretic and the cholestatic effects of ET-1 were abolished in animals pretreated with icv BQ-610 (selective ETA antagonist) but not with BQ-
788 (selective ETB antagonist). In addition, truncal vagotomy but not adrenergic blockade abolished ET-1 effects on bile secretion. Brain nitric
oxide was not involved in ET-1 response since L-NAME pretreatment failed to affect ET-1 actions on the liver. Portal venous pressure was
increased by centrally administered ET-1 being the magnitude of the increase similar with low and high doses of the peptide. These results show
that centrally applied ET-1 modified different bile flow fractions independent of hemodynamic changes. Lower doses of ET-1 increased bile acid
independent flow whereas higher doses decreased bile acid dependent flow. Vagal pathways through the activation of apparently distinct ETA
receptors mediated the cholestatic as well as the choleretic effects induced by ET-1. Present findings show that ET-1 participates in the central
regulation of bile secretion in the rat and give further insights into the complexity of brain–liver interaction.
© 2006 Elsevier B.V. All rights reserved.Keywords: Bile flow; Portal venous pressure; Bicarbonate; Bile acids; Glutathione1. Introduction
Endothelins are a family of related peptides that bind to
specific receptors widely expressed in numerous tissues and cell
types. The family comprises three isopeptides Endothelin-1
(ET-1), Endothelin-2 (ET-2) and Endothelin-3 (ET-3) that exert
different biological effects mainly in an autocrine and/or
paracrine fashion [1,2]. ET-1 is produced by the endothelium,
brain and gastrointestinal tract and functions as a locally
released peptide rather than a circulating hormone. ET-1 plays a
relevant role in the regulation of blood pressure either when
centrally or peripherally applied acting synergically with other⁎ Corresponding author. Tel.: +54 11 4964 8268x37; fax: +54 4791 9617.
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0167-0115/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.regpep.2006.04.001vasoactive substances like angiotensin II and catecholamines
[3]. ET-1 also regulates the synthesis and release of various
hormones and neurotransmitters [1,4,5].
Two distinct G-protein coupled receptors have been cloned
and characterized, ETA and ETB [2,6]. The former exhibits a
higher affinity for ET-1 and ET-2 than for ET-3 whereas the
latter binds the three isopeptides with similar affinity [2].
Alternative splice variants of ET receptors, coupled to distinct
intracellular signaling, have been reported but to date their
physiological or pathophysiological significance is unclear [2].
A receptor subtype named ETc has been cloned in Xenopus
laevis and shown to bind specifically ET-3 [7]. Although
functional studies support its existence, this receptor has not
been cloned in mammals yet [2,5,6]. Endothelin receptors are
expressed in several tissues including the endothelium, smooth









































Fig. 1. Effect of centrally applied ET-1 on bile flow (μl/min/100 g BW). ○:
Control; ▴: 1 fM ET-1; ■: 1 pM ET-1; ●: 0.1 nM ET-1 and ▾: 1 nM ET-1. ⁎:
pb0.05; ⁎⁎: pb0.01 and ⁎⁎⁎: pb0.001 vs. Control. Number of cases: 10–12.
BW: body weight.
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Fig. 2. Effect of centrally applied ET-1 on the output of bile acids (a), sodium (b)
and potassium (c).○: Control;▴: 1 fM ET-1 and▾: 1 nM ET-1. ⁎: pb0.05, ⁎⁎:
pb0.01 and ⁎⁎⁎: pb0.001 vs. Control. Number of cases: 8–10. BW: body
weight.
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among others [2,6].
Although ET-1 and receptors are widely expressed in the
CNS, the role of this peptide in the brain is not fully understood.
Several studies support its neuromodulatory role and suggest
that under physiological conditions it is released mainly from
neuronal cells [8,9]. Centrally applied ET-1 acts through ETA
receptors on autonomic neurons to modulate sympathetic
outflow [10]. Endothelins and their receptors show specific
distribution within the CNS [11]. The central areas where
endothelins are highly expressed include the dorsal vagal
complex (DVC) formed by the dorsal motor nucleus of the
vagus (DMNV) and the nucleus of the solitary tract (NTS),
which are the major sites for the autonomic regulation of the
gastrointestinal function. Various peptides and neuropeptides
influence gastrointestinal motility and/or digestive secretions
when applied to the brain. ET-1 through the activation of ETA
receptors acts in the lower brainstem to increase intragastric
pressure and gastric smooth muscle contractile activity through
vagally mediated pathways [12]. However little is known about
the central regulation of bile secretion by peptides as compared
with the wide literature on the brain regulation of gastric
secretion and gastrointestinal motor function. The secretion of
bile is increased by centrally applied neuropeptide Y whereas it
is reduced by the icv injection of bombesin or natriuretic
peptides [13–15].
In the present work we sought to establish the effect of
centrally applied ET-1 on bile secretion and to characterize the
receptors and the neural pathways involved. Our findings show
that ET-1 applied to the brain evoked opposite dose-dependent
regulatory effects on bile secretion through apparently distinct
ETA receptor subtypes via vagally mediated pathways.
2. Materials and methods
Sprague Dawley strain rats (Facultad de Farmacia y
Bioquímica, Universidad de Buenos Aires) weighing between
250 and 300 g were used in the experiments. The rats werehoused in steel cages and maintained at 22–24 °C in a
controlled room with 12-h light/dark cycle (light from 7:00 to
19:00 h). All experiments were conducted following the
recommendations of the National Institutes of Health guidelines
for the care and use of laboratory animals (NIH Publication
N85-23, 1985, revised 1996).
The following drugs were used: ET-1, BQ-610 and BQ-788
(selective ETA and ETB receptor antagonist, respectively)
(American Peptide Co., Ca, USA); N(ω)Nitro L-arginine methyl
ester (L-NAME), propranolol, phentolamine and methylene
blue (Sigma, St. Louis, MO). Other reagents were of the highest
grade available.
One week previous to bile secretion experiments, rats under
anesthesia were placed in a stereotaxic instrument (Kopf model


































































































Fig. 3. Effect of centrally applied ET-1 on the excretion rate of bicarbonate (a),
total glutathione (b) and proteins (c).○: Control;▴: 1 fM ET-1 and▾: 1 nM ET-
1. ⁎: pb0.05; ⁎⁎: pb0.01 and ⁎⁎⁎: pb0.001 vs. Control. Number of cases: 8–
10. BW: body weight.





















































Fig. 4. Effect of ETA receptor blockade by BQ-610 on 1 fM ET-1 (a) and 1 nM
ET-1 (b) induced changes on bile flow. ○: Control; □: 1 μM (a) or 1 mM (b)
BQ-610); ▴: 1 fM ET-1; ▾: 1 nM ET-1; ■: 1 μM BQ-610+1 fM ET-1 (a) or
1 mM BQ-610+1 nM ET-1 (b). ⁎: pb0.05; ⁎⁎: pb0.01 and ⁎⁎⁎: pb0.001 vs.
Control. Number of cases: 8–10. BW: body weight.
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cannula was introduced in the left ventricle of the brain as
previously described [13,14]. Briefly, rats were placed on a
stereotaxic frame and a small hole was drilled through the
appropriate area of the skull, the duramater pierced with a sharp
needle, and a 23-gauge stainless steel cannula placed in the left
lateral ventricle (1.3 mm posterior to the bregma, 2.0 mm lateral
to the midline and 4.0 mm ventral to the skull surface) [16]. The
cannula was anchored with a stainless steel screw in the skull to
protect the guide cannula and covered by dental acrylic. Rats
were placed in individual cages with food (Purina commercial
chow) and water ad libitum and allowed 96 h for recovery. For
bile secretion experiments rats were fasted for 14 h in order to
avoid possible changes in the release of different peptides and/
or hormones that may eventually influence bile secretion, andwere anesthetized with chloral hydrate (0.4 g/kg, ip). Through a
midline abdominal incision the common bile duct was exposed
and cannulated with a polyethylene catheter (PC-10 Intramedic,
USA) near its bifurcation to avoid contamination with
pancreatic juice. In those experiments where drugs were
intravenously administered, the left jugular vein was also
cannulated with a polyethylene catheter (PC-40 PL, Rivero and
Cía., Argentina). Rats remained anesthetized during bile
collection that was performed between 9:00 and 11:00 to
avoid possible circadian changes [17]. Body temperature was
kept at 37 °C with a heating pad.
2.1. Effect of central ET-1 on bile flow and biliary constituents
Bile secretion was allowed to flow for 10 min (basal period)
to stabilize the flow. ET-1 (1 fM, 1 pM, 0.1 and 1 nM)
(experimental groups) or artificial cerebrospinal fluid (ACSF)
(control group) was icv applied at a rate of 1 μl/min (total
volume: 2 μl). The ACSF used was of the following




−: 0.5; Glucose: 4.3
and urea: 6.5 [13,14]. Bile was collected every 5 min for the first
15 min and every 15 min for 60 min in ice-cold microcentrifuge
tubes. The accuracy of icv injections was assessed at the end of
each experiment by icv administration of 1 μl methylene blue.

























































Fig. 5. Effect of central ETB receptor blockade by BQ-788 on 1 fM ET-1 (a) and
1 nM ET-1 (b) induced changes on bile flow. ○: Control;□: 1 μM (a) or 1 mM
(b) BQ-788; ▴: 1 fM ET-1; ▾: 1 nM ET-1; ■: 1 μM BQ-788+1 fM ET-1 or 1
mM BQ-788+1 nM ET-1. ⁎: pb0.05; ⁎⁎: pb0.01; ⁎⁎⁎: pb0.001 vs. Control; ‡:
pb0.05 and ‡‡: pb0.01 vs. BQ-788. Number of cases: 8–10. BW: body weight.




















































Fig. 6. Effect of centrally applied 1 fM ET-1 (a) and 1 nM ET-1 (b) on bile flow
in rats with truncal vagotomy (VT).○: Control;□: VT;▴: 1 fM ET-1;▾: 1 nM
ET-1 and ■: VT+1 fM ET-1 (a) or VT+1 nM ET-1 (b). ⁎: pb0.05; ⁎⁎: pb0.01
and ⁎⁎⁎: pb0.001 vs. Control; ‡: pb0.05 and ‡‡: pb0.01 vs. VT. Number of
cases: 8–10. BW: body weight.
57M.R. Rodríguez et al. / Regulatory Peptides 135 (2006) 54–62Animals were killed and through the opening of the skull the
brain was removed, and the presence of methylene blue was
strictly verified in the lateral ventricle.
Doses of 1 fM and 1 nM ET-1 were used to determine the
receptors and mechanisms involved in ET-1 response on bile
secretion.
Biliary sodium, chloride, potassium, and bicarbonate were
measured in each sample. The concentration of bile acids and
phospholipids in each sample was assessed by the 3α-
hydroxysteroid dehydrogenase assay and the modified Bartleet
method, respectively [18,19]. The concentration of total
glutathione was measured using glutathione reductase and
5,5′-dithiobis 2-nitrobenzoic acid [20]. Proteins were deter-
mined according to Lowry et al. [21]. Bile flow was calculated
as μl/min/100 g body weight and with these values the excretion
rate of the different constituents of bile were determined.
2.2. Endothelin receptors in the brain
To determine the brain endothelin receptor subtype involved
in ET-1 response selective ETA (BQ-610) and ETB (BQ-788)
receptor antagonists were used. BQ-610 (1 μM or 1 mM) and
BQ-788 (1 μM or 1 mM) were dissolved in saline and centrally
injected 5 min prior to the icv administration of 1 fM or 1 nM
ET-1, respectively. Collection of bile samples was performed as
described for basal bile secretion experiments.2.3. Participation of the autonomic nervous system in ET-1
response
When applied to the brain diverse neuropeptides affect
gastrointestinal functions through the autonomic nervous
system [15]. Therefore we sought to establish whether the
parasympathetic or the sympathetic systems were involved in
ET-1 response. The role of the vagal pathway was evaluated in
animals with bilateral truncal vagotomy. Cervical vagotomy
was not performed to avoid possible hemodynamic alterations
resulting from the section of the cardiac vagal branches.
Bilateral truncal vagotomy was performed by sectioning both
branches of the vagus and vagal afferents at the level of the
lower esophagus 2 h before bile secretion experiments
[13,14,22]. After icv ET-1 (1 fM or 1 nM) bile samples were
collected as indicated above.
The contribution of the sympathetic nervous system to ET-1
response was assessed by combined administration of phentol-
amine (α-adrenergic antagonist) and propranolol (β-adrenergic
antagonist). A bolus of 0.5 mg/kg phentolamine was intrave-
nously injected in bolus 30 min before ET-1 central injection.
The antagonist was then infused at a constant rate of 0.2 mg/kg/
h throughout the period of bile collection. Propranolol (0.5 mg/
kg) was intravenously administered 30 min before icv ET-1
injection [13,14,22]. ET-1 (1 fM or 1 nM) was icv injected and






















































Fig. 7. Effect of adrenergic blockade by phentolamine (P) and propranolol (Pr)
on 1 fM ET-1 (a) and 1 nM ET-1 (b) bile flow-induced changes.○: Control;□:
P+Pr; ▴: 1 fM ET-1; ▾: 1 nM ET-1; ■: P+Pr+1 fM ET-1 (a) or P+Pr+1 nM
ET-1 (b). ⁎: pb0.05; ⁎⁎: pb0.01 and ⁎⁎⁎: pb0.001 vs. Control; ‡: pb0.05; ‡‡:
pb0.01 and ‡‡‡: pb0.001 vs. P+Pr. Number of cases: 8–10. BW: body weight.
























































Fig. 8. Effect of NO synthase blockade by L-NAME (3.8 μM) on 1 fM ET-1 (a)
and 1 nM ET-1 (b) bile flow-induced changes. ○: Control; □: L-NAME; ▴:
1 fM ET-1;▾: 1 nM ET-1;■: L-NAME+1 fM ET-1 (a) or L-NAME+1 nM ET-
1 (b). ⁎: pb0.05; ⁎⁎: pb0.01 and ⁎⁎⁎: pb0.001 vs. Control; ‡: pb0.05; ‡‡:
pb0.01 and ‡‡‡: pb0.001 vs. L-NAME. Number of cases: 6–8. BW: body
weight.
58 M.R. Rodríguez et al. / Regulatory Peptides 135 (2006) 54–62samples collected as detailed for spontaneous bile secretion
experiments.
2.4. Participation of brain nitric oxide (NO) in ET-1 response
The contribution of NO to ET-1 response was evaluated
based on experimental observations showing that NO synthase
containing preganglionic neurons are present in the DVC and
project to extensive regions of the gastrointestinal tract [23]. To
investigate the participation of a central NO pathway in ET-1
response, rats were pretreated with icv 3.8 μM L-NAME 15 min
prior to 1 fM or 1 nM ET-1 injection. Bile samples were
collected as previously described. The dose of L-NAME used in
the present study completely inhibits NO synthase activity in
the brain but evokes no hemodynamic changes.
2.5. Portal venous pressure
Portal venous pressure was estimated by splenic pulp pressure
as previously described [24]. Briefly, the spleen was exposed by
retraction of the perisplenic fat carefully avoiding undue
manipulation. A fluid-filled needle end cannula was inserted
into the spleen and fixed by applying cyanoacrylate glue. The
catheter was connected to a pressure transducer (Staham 923Db)
and signals recorded on a polygraph (Coulbourn Inst., USA).After a period of stabilization ET-1 was injected in the lateral
ventricle and portal venous pressure recorded. Control rats were
injected with the same volume of ACSF (2 μl). Portal venous
pressure was monitored during the first 5 min and then every
10 min for 60 min.
2.6. Statistical analysis
The statistical analysis was performed using ANOVA
followed by the Student–Newman Keuls test. Portal venous
pressure results were analyzed by the Student “t” test. Results
are expressed as the mean±S.E.M. p values of 0.05 or less were
considered statistically significant.
3. Results
Results showed that centrally applied ET-1 exhibited
opposite effects on bile secretion depending on the given dose
(Fig. 1). Lower doses of ET-1 enhanced bile flow whereas
higher doses decreased it. One fM ET-1 increased bile secretion
at all studied times whereas 1 pM ET-1 induced no changes
during the first collection periods (5, 10, 15 and 20 min) but it
enhanced bile flow at 30 min up to the end of the experiment.
Table 1
Effect of icv ET-1 (1 fM and 1 nM) on portal venous pressure (mmHg)
Time ET-1 (1 nM) (mmHg) ET-1 (1 fM) (mmHg)
0 s 4.1±0.7 4.1±0.7
10 s 5.7±0.8⁎ 6.2±0.5⁎⁎
20 s 6.4±0.1⁎⁎ 5.9±0.6⁎
30 s 5.8±0.3⁎ 6.2±0.5⁎⁎
1 min 5.9±0.4⁎ 6.3±0.4⁎⁎
2 min 6.2±0.2⁎⁎ 6.2±0.3⁎
3 min 5.8±0.2⁎ 5.9±0.1⁎⁎
5 min 6.5±0.3⁎⁎ 6.1±0.3⁎⁎
10 min 5.7±0.2⁎ 5.8±0.3⁎
⁎: pb0.05 and ⁎⁎: pb0.01 vs. time=0. Number of cases: 4–6.
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collection period returning then to control levels whereas 1 nM
ET-1 decreased bile flow at all experimental periods. Both the
choleretic and cholestatic effects evoked by ET-1 were evident
at 5 min after the administration of the peptide. These findings
suggest that according to the dose injected ET-1 may trigger
different intracellular mechanisms in the brain resulting in either
an increase or a decrease in bile flow. Doses of 1 fM and 1 nM
ET-1, which increased and decreased bile flow respectively,
were used to investigate the neural pathways and receptors
involved.
Different biliary constituents were assessed in order to de-
termine the fraction of bile affected by ET-1 applied to the brain.
Bile acid output was decreased by 1 nM ET-1 but unaltered by
1 fM ET-1 (Fig. 2a). Further, the excretion of sodium and
potassium was also decreased by 1 nM ET-1 but not by 1 fM
ET-1 (Fig. 2b and c). On the other hand, chloride excretion was
not modified by any dose of ET-1 (data not shown) but bicar-
bonate output was increased by 1 fM ET-1 and unchanged by
1 nM ET-1 (Fig. 3a). Centrally applied ET-1 modified neither
phospholipids (data not shown) nor glutathione excretion at any
dose (Fig. 3b). Although 1 nM ET-1 did not affect protein
output, 1 fM ET-1 increased it (Fig. 3c).
In order to determine the receptor subtype activated by ET-1
in the brain, experiments were performed in animals pretreated
with icv selective endothelin antagonists. Results showed that
neither BQ-610 (ETA antagonist) nor BQ-788 (ETB antagonist)
modified bile flow. BQ-788 did not affect either the cholestatic
or the choleretic response of centrally injected ET-1 excluding
thus the participation of ETB receptors (Fig. 4a and b). However
both the stimulatory and inhibitory actions of ET-1 were com-
pletely abolished in the presence of BQ-610 supporting that
both effects were mediated by the activation of central ETA
receptors (Fig. 5a and b).
The participation of the vagal pathway was assessed in rats
with bilateral truncal vagotomy. Results showed that truncal
vagotomy abolished the effect of 1 fM and 1 nMET-1 on bile flow
supporting that the parasympathetic system mediates central ET-1
response on the liver (Fig. 6a and b). On the other hand, adrenergic
blockade by phentolamine and propranolol affected neither basal
nor ET-1 induced changes in bile flow (Fig. 7a and b).
The role of brain NO was evaluated by icv L-NAME
administration. Blockade of NO synthesis affected neither basal
flow nor ET-1 choleretic or cholestatic effects excluding theparticipation of NO in the central regulation of bile flow by ET-
1 (Fig. 8a and b).
Portal venous pressure was significantly increased by icv
injection of 1 fM and 1 nM ET-1 and abolished by ETA
blockade as previously shown by other authors (data not shown)
[26]. The magnitude of portal pressure elevation was similar
with both doses of ET-1 (only results up to 10 min are shown)
(Table 1).
4. Discussion
The major finding of the present work was that ET-1 through
a vagal-mediated pathway participates in the central modulation
of bile secretion by activating apparently distinct ETA receptors
in the brain.
The brain–liver interaction has been widely studied as
regards the control of glucose metabolism where the hypothal-
amus plays a relevant role [25]. However little is known about
the existence of a central regulation of bile secretion, although
several peptides and neuropeptides have been shown to
influence bile flow when they are applied to the brain [13–15].
In the present work centrally applied ET-1 modified bile flow
exhibiting opposite effects depending on the given dose. The
lowest dose of ET-1 (1 fM) used in the present study increased
bile flow whereas the highest dose (1 nM) decreased it. Both the
cholestatic and the choleretic effects induced by ET-1 were
evident at 5 min after the injection of the peptide. Surprisingly,
both the stimulatory as well as the inhibitory effect of ET-1 on
bile flow were mediated by the activation of central ETA
receptors. Pretreatment with BQ-610 (selective ETA antagonist)
abolished the stimulatory as well as the inhibitory effect of ET-1
on bile flow, whereas the administration of a selective ETB
antagonist (BQ-788) failed to modify any response. These
findings suggest that the activation of ETA receptors by ET-1
may trigger different intracellular signaling pathways in the
CNS according to the dose resulting in either decreased or
increased bile flow. Similar findings were observed by other
authors but in isolated perfused livers [26]. ET-1 dose-
dependently raises portal venous pressure through ETA receptor
activation but at a high dose it causes decreases in bile flow and
bile acid excretion whereas at low doses it enhances it despite
pressure elevation [26]. These results as well as our findings
suggest the existence of distinct ETA receptors. In fact, binding,
pharmacological as well as functional studies support the
existence of more than the two conventional receptor subtypes
ETA and ETB that operate within the nanomolar and picomolar
ranges [2]. Distinct ET receptors that possess super high affinity
sites (picomolar range) are present in the CNS and peripheral
tissues [2]. These receptors share some structural and functional
features with the previously identified high affinity receptors
(nanomolar range), but nevertheless show some differences in
structure as well as in biological activity. Although the ETB
receptor has been more studied regarding this issue, experi-
mental evidence supports that the ETA receptor also shows high
and super high affinity binding sites. In this respect, two
functionally distinct ETA subtypes of binding sites were
identified in rat mesangial cells [27]. Moreover characterization
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indicates the involvement of two ETA receptor subtypes [28].
Similar findings were observed in the rat atrium, C6-gliomal
cells and fibroblasts [2]. The activation of the high and super
high affinity receptors triggers different intracellular signaling.
In cerebral slices ET-1 induces phospholipase C activity at
concentrations higher than 500 pM but not at lower concentra-
tions suggesting the operation of different receptors [2,29].
Those of the nanomolar sites are coupled to the phosphoinosi-
tide hydrolysis pathway whereas those of the picomolar sites
were found to be involved in signal transduction via cAMP and
cGMP pathways [30–32]. Whether these receptors are identical
to the conventional receptors, having similar biological
properties and the ability to oscillate between two affinity
states (picomolar and nanomolar sites) or whether they
represent distinct receptor subtypes remains to be elucidated
[2]. In the present work ET-1 applied to the brain evoked
opposing actions on bile flow depending on the dose suggesting
the activation of distinct ETA receptor subtypes within the brain.
Diverse peptides applied to the brain mediate their effect
through the autonomic nervous system [15]. Vagal stimulation
tends to increase bile flow whereas adrenergic stimulation
reduces it [33]. In view of the observation that ET-1 exerted a
choleretic or cholestatic effect depending on the dose, the
contribution of the autonomic nervous system to ET-1 response
was investigated. The participation of a vagal pathway was
evaluated in rats with bilateral truncal vagotomy. Vagotomy by
itself evoked no changes in bile flow although a reducing trend
was observed compared with the control group but it abolished
both the stimulatory as well as the inhibitory effect of ET-1 on
bile secretion. These findings support that the parasympathetic
system mediates the opposing actions of ET-1 on bile flow and
further suggest that the DVC is likely a target site of action for
this peptide. In fact, autoradiographic studies have documented
the presence of ET-1 binding sites in the DVC [34]. The DMNV
of the medulla oblongata is a major site of origin of vagal
preganglionic fibers that control the gastrointestinal system.
This nucleus together with the NTS (the major visceral sensory
relay cell group in the brain) is often referred to as the DVC.
Throughout the brain ET-1 displays distinct binding densities,
immunoreactivity and messenger RNA. When injected into a
lateral cerebral ventricle ET-1 evokes a remarkably discrete
pattern of c-fos expression in the brainstem, where the
expression is most marked in the NTS and the DMNV [11].
The pattern of c-fos expression provides direct cellular evidence
for ET's sites of action in the CNS. The ETA receptor is
responsible for c-fos induction indicating that ET-1 derived c-
fos induction is receptor-mediated [11]. These findings support
that ET-1 evoked response on bile secretion is likely mediated
by modifications in the neuronal activity of the DVC triggered
by ETA receptor activation. At a high dose ET-1 would decrease
vagal activity whereas at a low dose it would increase it. Other
ET-1 effects on the gastrointestinal tract mediated by the vagus
and central ETA receptors have also been reported [12].
Although ET-1 action on the liver was vagally mediated, we
also investigated if there was any contribution by the
sympathetic nervous system based on the evidences showingthat ET-1 applied to the brain modulates sympathetic outflow
and that it also modifies norepinephrine release in the
hypothalamus and other brain areas [4,5,10]. In addition, the
observation that 1 nM ET-1 reduced bile flow suggested an
increased sympathetic outflow to the liver since enhanced
sympathetic activity is associated with reduced bile flow [33].
Blockade of α- and β-adrenoceptors failed to affect basal or ET-
1 responses on bile secretion supporting that ET-1-evoked
sympathetic outflow does not contribute to changes in bile flow,
although it mediates peripheral vascular effects as previously
reported [10].
NO is synthesized in neurons and acts as a classical
neurotransmitter or neuromodulator to influence a variety of
physiological functions including those of the digestive system
[23]. NOS containing preganglionic neurons are present in the
DVC and project to extensive regions of the gastrointestinal
tract [23]. Therefore we evaluated whether brain NO was
involved in ET-1 choleretic or cholestatic response. Pretreat-
ment with icv L-NAME failed to affect basal flow and ET-1
evoked changes in bile excluding the contribution of brain NO.
We next evaluated the fraction of bile flow affected by icv
ET-1. Bile flow is conceptually divided into two fractions, bile
acid dependent flow (BADF) which depends upon the
canalicular excretion of bile acids and the bile acid independent
flow (BAIF) whose origin is still controversial [35]. Various
studies support that bicarbonate excretion accounts for BAIF
although the output of glutathione and its derivatives have been
also shown to play a major role. The contribution of ductal
secretion to total bile flow is important in many species, but not
in rodents [35]. Central administration of 1 nM ET-1 that
diminished bile flow, also reduced bile acid output but affected
neither bicarbonate nor glutathione excretion. Furthermore ET-1
at this concentration also decreased the excretion rate of sodium
and potassium that are two electrolytes associated with BADF.
These findings support that the inhibitory effect on bile flow
evoked by 1 nM ET-1 resulted from the reduction of BADF. On
the other hand, centrally applied 1 fM ET-1 that increased bile
flow affected neither bile salt nor sodium and potassium
excretions supporting that the stimulatory effect evoked by icv
ET-1 on total bile flow did not result from an increase in BADF.
Nevertheless 1 fM ET-1 increased bicarbonate excretion
without affecting glutathione output. Taken together these
findings suggest that the choleretic effect evoked by 1 fM ET-1
resulted from an increase in BAIF. Increases in BAIF only due
to an increase in bicarbonate excretion have been previously
reported [36]. Surprisingly biliary protein output was enhanced
by 1 fM ET-1 although it was not modified by a higher dose of
the peptide (1 nM). The relevance of this finding is presently
unknown. The excretion of proteins in bile is associated neither
with BADF nor BAIF generation [35]. In fact most of the biliary
proteins derive from the plasma pool and reach bile by
transcellular or paracellular pathways [35]. The observation
that ET-1 through the ETA receptor modified different fractions
of bile flow depending on the given dose further supports the
participation of distinct ETA receptor subtypes coupled to
different intracellular signaling pathways as previously
discussed.
61M.R. Rodríguez et al. / Regulatory Peptides 135 (2006) 54–62ET-1 is a potent vasoactive peptide involved in the central as
well as peripheral regulation of blood pressure [10,37]. In
addition, systemic administration of ET-1 dose-dependently
increases portal venous pressure whereas the icv injection causes
changes in regional blood flows including the portal flow [37].
Therefore we sought to establish whether the vasoactive
properties of ET-1 could mediate the changes in bile secretion.
Both 1 fM and 1 nM ET-1, that increased and decreased bile flow
respectively, evoked a sustained increase in portal venous
pressure. The magnitude of the increase was similar for both
doses and abolished by ETA blockade as shown by other authors
[26]. Both doses of ET-1 increased portal venous pressure but the
higher dose decreased bile flow whereas the lower dose increased
it. These findings support that the cholestatic and choleretic
effects induced by different doses of ET-1 are independent of
hemodynamic changes. In fact, changes in portal venous pressure
do not necessarily reflect on bile flow unless these variations are
sufficiently marked so as to overcome the hepatic autoregulatory
mechanisms that operate within a range to maintain a constant
blood flow along the sinusoids. Furthermore, although ET-1
enhances sympathetic outflow to the liver peripherally adrenergic
blockade did not prevent ET-1 response on bile secretion.
Previous reports show that in the isolated perfused liver ET-1
also exerts cholestatic or choleretic effects [26,38,39]. The
cholestatic effect was ascribed to hemodynamic changes where-
as the choleretic action was attributed to a direct effect on the
hepatocyte function [26,38]. Most of the literature regarding
ET-1 and hepatic function refers to its role in pathophysiological
situations [40].
Present results show that the icv administration of ET-1
through a vagal pathway evoked opposing actions on bile flow
mediated by the activation of apparently distinct ETA receptors
in the brain. The fraction of bile flow affected by ET-1 was
dependent on the dose of the peptide and independent of
hemodynamic changes considering that both doses evoked an
elevation of portal venous pressure approximately of the same
magnitude. The present work further supports the physiological
relevance of the action of neuropeptides on brain sites to control
gastrointestinal function and reveals new insights into the
brain–liver interaction.
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